Magpale, Nicasio R.
HRN: 22-61-27 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/12/2025
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
12/12/2025
12/18/2025
IV
750mg LD, Then 500mg Q48
750mg LD, Then 500mg Q48
Sepsis, HAP
Checking Final Appropriateness
Indication: Empirical Escalation Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes